Xeris Pharmaceuticals ROA 2024

Xeris Pharmaceuticals Aktienanalyse

What does Xeris Pharmaceuticals do?

Xeris Pharmaceuticals Inc is a US pharmaceutical company that was founded in 2005. The company is headquartered in Chicago and is listed on the Nasdaq stock exchange. The business model of Xeris Pharmaceuticals is focused on providing patients and medical professionals with a wide range of products and services that improve patients' lives while promoting the development of effective and safe drugs. Xeris Pharmaceuticals focuses on the development of drugs made from peptides and proteins. The aim is to provide innovative drugs to patients with rare diseases or unmet therapeutic needs. Over the years, Xeris Pharmaceuticals has diversified into various sectors. One of the most important sectors is the diabetes industry. In this area, the company offers the Gvoke product family, a lightweight auto-injection method designed for adults, adolescents, and children with type 1 diabetes, as well as adults with type 2 diabetes. The Gvoke product is intended for patients with severe hypoglycemia and provides a quick and easy way to treat life-threatening hypoglycemic episodes. Another important sector for Xeris Pharmaceuticals is the neurology industry. In this area, the company has developed an injection device called XeriSol, specifically designed for the treatment of epilepsy or neurological seizures. The active ingredient used is diazepam, which has a rapid and reliable effect on seizures. Xeris Pharmaceuticals is also involved in cancer treatment. The company has developed a pituitary hormone analog called Pasireotide, which is used to treat Cushing's disease, a rare condition caused by hormone overproduction. The drug fits well into Xeris Pharmaceuticals' business model as it is peptide-based and offers better efficacy and safety than other drugs in this area. Overall, Xeris Pharmaceuticals has a strong pipeline of drugs that offer the company great potential for future growth. The development of innovative drugs and drug combinations is an important strategy for Xeris Pharmaceuticals to help patients with rare diseases or unmet therapeutic needs. In this regard, Xeris Pharmaceuticals has also formed partnerships with other leading pharmaceutical companies such as Sanofi, Eli Lilly, and Roche. These partnerships allow the company to accelerate its drug development and offer its products in the international market. In conclusion, the success story of Xeris Pharmaceuticals shows that the company is an important player in the pharmaceutical industry and plays a crucial role in the development of innovative, safe, and effective drugs for patients with rare diseases and unmet therapeutic needs. With its wide range of products, partnerships, and strong pipeline of innovative drugs, Xeris Pharmaceuticals is a company that has great potential for successful growth in the future. Xeris Pharmaceuticals ist eines der beliebtesten Unternehmen auf Eulerpool.com.

ROA Details

Understanding Xeris Pharmaceuticals's Return on Assets (ROA)

Xeris Pharmaceuticals's Return on Assets (ROA) is a key performance indicator that measures the company's profitability in relation to its total assets. It is calculated by dividing the net income by the total assets. A higher ROA indicates efficient asset utilization to generate profits, reflecting managerial effectiveness and financial health.

Year-to-Year Comparison

Comparing Xeris Pharmaceuticals's ROA year-over-year provides insights into the company’s operational efficiency and asset utilization trends. An increasing ROA demonstrates enhanced asset efficiency and profitability, while a declining ROA can indicate operational or financial challenges.

Impact on Investments

Investors consider Xeris Pharmaceuticals's ROA as a crucial metric to evaluate the company’s profitability and efficiency. A higher ROA signifies that the company is effectively utilizing its assets to generate profits, making it a potentially attractive investment.

Interpreting ROA Fluctuations

Variations in Xeris Pharmaceuticals’s ROA can be attributed to changes in net income, asset purchases, or operational efficiencies. Analyzing these fluctuations assists in assessing the company's financial performance, management efficiency, and strategic financial positioning.

Frequently Asked Questions about Xeris Pharmaceuticals stock

What is the Return on Assets (ROA) of Xeris Pharmaceuticals this year?

The Return on Assets (ROA) of Xeris Pharmaceuticals is -0.19 undefined this year.

What was the ROA of Xeris Pharmaceuticals compared to the previous year?

The ROA of Xeris Pharmaceuticals has increased by -29.8% compared to the previous year.

What consequences do high ROA have for investors of Xeris Pharmaceuticals?

A high ROA is advantageous for investors of Xeris Pharmaceuticals, as it indicates that the company efficiently utilizes its assets and generates good profits.

What are the consequences of low ROA for investors in Xeris Pharmaceuticals?

A low ROA can be unfavorable for investors of Xeris Pharmaceuticals as it indicates that the company is inefficiently utilizing its assets and may potentially achieve lower profits.

How does an increase in the ROA of Xeris Pharmaceuticals affect the company?

An increase in ROA of Xeris Pharmaceuticals can be an indicator of improved efficiency in asset utilization and higher profitability.

How does a reduction in ROA of Xeris Pharmaceuticals impact the company?

A reduction in the ROA of Xeris Pharmaceuticals can be an indicator of lower asset efficiency and profitability.

What are some factors that can influence the ROA of Xeris Pharmaceuticals?

Some factors that can influence the ROA of Xeris Pharmaceuticals include revenue, operating costs, asset structure, and industry average.

Why is the ROA of Xeris Pharmaceuticals important for investors?

The ROA of Xeris Pharmaceuticals is important for investors as it is an indicator of the company's profitability and efficiency in utilizing assets. It provides investors with information on how well the company utilizes its resources to generate profits.

What strategic measures can Xeris Pharmaceuticals take to improve ROA?

To improve ROA, Xeris Pharmaceuticals can take measures such as cost savings, revenue growth, optimizing asset structure, and diversifying its business activities. It is important for the company to conduct a thorough review of its financial situation to determine the best strategic measures to improve ROA.

How much dividend does Xeris Pharmaceuticals pay?

Over the past 12 months, Xeris Pharmaceuticals paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Xeris Pharmaceuticals is expected to pay a dividend of 0 USD.

What is the dividend yield of Xeris Pharmaceuticals?

The current dividend yield of Xeris Pharmaceuticals is .

When does Xeris Pharmaceuticals pay dividends?

Xeris Pharmaceuticals pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Xeris Pharmaceuticals?

Xeris Pharmaceuticals paid dividends every year for the past 0 years.

What is the dividend of Xeris Pharmaceuticals?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Xeris Pharmaceuticals located?

Xeris Pharmaceuticals is assigned to the 'Health' sector.

Wann musste ich die Aktien von Xeris Pharmaceuticals kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Xeris Pharmaceuticals from 11/3/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 11/3/2024.

When did Xeris Pharmaceuticals pay the last dividend?

The last dividend was paid out on 11/3/2024.

What was the dividend of Xeris Pharmaceuticals in the year 2023?

In the year 2023, Xeris Pharmaceuticals distributed 0 USD as dividends.

In which currency does Xeris Pharmaceuticals pay out the dividend?

The dividends of Xeris Pharmaceuticals are distributed in USD.